By Nigam Arora & Dr. Natasha Arora
VF Corp (VFC) belongs to the strategy of buying good companies near the lows when the problems are temporary.
There are very nice profits on the VFC position. The stock is trading at $21.16 as of this writing, up about 23% for the day on better than expected earnings.
Buyout Target
VFC remains a buyout target. To date, 199 Arora Portfolio companies have been bought out, producing a fortune for members who consistently invest in buyout targets.
Target Zone
The target zone remains $28 – $32.
This is a very long term position.
What To Do Now
Those in the stock may consider taking partial profits right around here and consider rising the stop zone on the rest to $16.73 – $17.43 to protect profits. Consider holding the rest.
Those not in the stock may consider waiting for a new signal.
Note: Signal(s) to enter, add, reduce, exit, hold or change.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.